Esperion Therapeutics to delist from Nasdaq

Esperion Therapeutics, Inc. is removing its common stock from listing and registration on the Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934.

Rhea-AI Filing Summary

Esperion Therapeutics, Inc. is removing its common stock from listing and registration on the Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934. Nasdaq certifies that it has complied with its rules and the applicable provisions of 17 CFR 240.12d2-2 to strike this class of securities from listing and/or withdraw its registration.

Filing Explained

Esperion’s common stock is subject to Nasdaq delisting and withdrawal of Section 12(b) registration under the July 13 Form 25 notification.

The July 13, 2026 Form 25-NSE is a notification concerning removal of Esperion Therapeutics common stock from Nasdaq listing and withdrawal of its Section 12(b) registration. The disclosed consequence is a change in the stock’s exchange-listing and Section 12(b) registration status, while the filing does not state that the common stock itself is cancelled.

The filing says Nasdaq has complied with its rules to strike the class from listing and withdraw its exchange registration, and separately states that the issuer complied with requirements for voluntary withdrawal.

Key Figures

Commission File Number: 001-35986 Rule citation: 17 CFR 240.12d2-2(b) Rule citation: 17 CFR 240.12d2-2(c)

3 metrics

Commission File Number 001-35986 File number for Esperion Therapeutics, Inc. under the Exchange Act

Rule citation 17 CFR 240.12d2-2(b) Cited as the basis for the Exchange striking the class of securities

Rule citation 17 CFR 240.12d2-2(c) Cited regarding issuer compliance for voluntary withdrawal from listing

Key Terms

Form 25, Section 12(b), 17 CFR 240.12d2-2, withdrawal of the class of securities

4 terms

Form 25 regulatory

"FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION"

A Form 25 is an official filing with the U.S. Securities and Exchange Commission used to remove a company's stock or other security from a national exchange list. Investors should care because delisting often means less visibility, lower trading volume and wider price swings—similar to a product moving from a major supermarket to a small local market, which can make buying, selling and valuing the security more difficult.

Section 12(b) regulatory

"REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934"

Section 12(b) of the U.S. Securities Exchange Act requires securities listed on a national stock exchange to be registered with the U.S. Securities and Exchange Commission (SEC) and to follow regular public reporting and disclosure rules. For investors, a 12(b) listing generally means more routine financial updates, regulatory oversight and easier buying and selling—like a storefront that must display its inventory and prices, making it simpler to inspect and trade the product.

17 CFR 240.12d2-2 regulatory

"Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied"

A U.S. Securities and Exchange Commission rule that describes the conditions and procedural steps for a security to be removed from public registration or reporting under the Securities Exchange Act of 1934. For investors, it matters because it explains when a company’s shares can stop being subject to regular disclosure and exchange listing rules — similar to knowing when a publicly tracked product will be discontinued and no longer send updates, which affects transparency and liquidity.

withdrawal of the class of securities regulatory

"governing the voluntary withdrawal of the class of securities from listing"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What action is Esperion Therapeutics (ESPR) taking in this Form 25 filing?

Esperion Therapeutics, Inc. is removing its common stock from listing and registration on the Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934, as reflected in this Form 25 notification.

Which securities of Esperion Therapeutics (ESPR) are affected by this delisting?

The filing covers Esperion Therapeutics’ common stock as the affected class of securities. Nasdaq indicates that this class is being struck from listing and/or withdrawn from registration pursuant to 17 CFR 240.12d2-2.

Which exchange is Esperion Therapeutics (ESPR) leaving according to this document?

Esperion Therapeutics’ common stock is being removed from listing on the Nasdaq Stock Market LLC. Nasdaq certifies that it has followed its own rules and 17 CFR 240.12d2-2 to effect this removal.

Under what regulatory authority is Esperion Therapeutics (ESPR) being delisted?

The delisting proceeds under Section 12(b) of the Securities Exchange Act of 1934 and 17 CFR 240.12d2-2. The document references both Rule 12d2-2(b) and Rule 12d2-2(c) as the governing provisions.

Who signed the Nasdaq certification related to Esperion Therapeutics (ESPR)?

The certification on behalf of Nasdaq Stock Market LLC is signed by Tara Petta, listed with the title AVP. Nasdaq states it has reasonable grounds to believe it meets all requirements for filing this Form 25 notification.

What is the Commission File Number for Esperion Therapeutics (ESPR) in this Form 25?

The Commission File Number associated with Esperion Therapeutics, Inc. in this Form 25 is 001-35986. This number uniquely identifies the issuer’s registration under the Securities Exchange Act of 1934.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/13/2026 - 09:19 AM EDT Learn about SEC filing dates

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-35986

Issuer:	Esperion Therapeutics, Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	3891 Ranchero Drive, Suite 150
	Ann Arbor	MICHIGAN	48108
Telephone number:					(734) 887-3903

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Stock

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2026-07-13	By	Tara Petta		AVP
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.